"Myeloproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Descriptor ID |
D009196
|
MeSH Number(s) |
C15.378.190.636
|
Concept/Terms |
Myeloproliferative Disorders- Myeloproliferative Disorders
- Disorder, Myeloproliferative
- Disorders, Myeloproliferative
- Myeloproliferative Disorder
|
Below are MeSH descriptors whose meaning is more general than "Myeloproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Myeloproliferative Disorders".
This graph shows the total number of publications written about "Myeloproliferative Disorders" by people in this website by year, and whether "Myeloproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 2 | 0 | 2 |
2021 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloproliferative Disorders" by people in Profiles.
-
Germline POT1 Deregulation Can Predispose to Myeloid Malignancies in Childhood. Int J Mol Sci. 2021 Oct 26; 22(21).
-
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes. Stem Cell Reports. 2021 11 09; 16(11):2768-2783.
-
Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms. Blood Adv. 2021 09 14; 5(17):3373-3376.
-
Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells. Ann Hematol. 2021 Dec; 100(12):2943-2956.
-
Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021 04 01; 28(4):637-652.e8.
-
Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm. Ann Hematol. 2021 Jan; 100(1):97-104.
-
Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Leukemia. 2020 04; 34(4):1062-1074.
-
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-a via JAK1/STAT1 activation. Leukemia. 2019 04; 33(4):995-1010.